Literature DB >> 13449237

The pathogenesis of hemophilia; an experimental analysis of the anticephalin hypothesis in hemophilic dogs.

J B GRAHAM, E M BARROW.   

Abstract

It has been possible to duplicate in the hemophilic dog four of the major experiments which have suggested in humans an "anticephalin" hypothesis for the pathogenesis of hemophilia. The experiments in the dog have been considerably extended, as compared with the human experiments, by a variety of techniques. I. Asbestos was placed in contact with hemophilic dog plasma, and the clotting time became shorter. When transfused, this plasma had no effect on the defective prothrombin utilization of hemophilic dogs, in contrast to untreated normal plasma. II. The ionic strength of native dog plasma and dog plasma citrated (38 per cent sodium citrate) then recalcified (0.2 M CaCl(2)) were calculated. The ionic strength of the native plasma was approximately 0.15 while that of the citrated plasma was approximately 0.21. Conductivity and freezing point determinations on the plasmas described above were consistent with the idea that the ionic strength of the citrated plasma was significantly higher. The biphasic dilution curve, to which much significance has been attached in arriving at the "anticephalin" hypothesis, can be produced readily in the dog. Diluting dog plasma with "iso-ionic" or "hyper-ionic" NaCl solution abolished the biphasic phenomenon. Dilution with distilled water exaggerated the biphasic curve. These experiments suggest that the biphasic curve is an artifact of uncontrolled ionic strength. III. The prothrombin utilization rates of undiluted whole hemophilic dog blood and hemophilic dog blood diluted 1:2 with 0.85 per cent NaCl were found to be the same. IV. Ether extraction of both normal and hemophilic dog plasma removed fibrinogen and reduced somewhat the concentration of prothrombin. In treated normal plasma AHF was reduced to the level of untreated hemophilic plasma, thus producing a quasi-hemophilic plasma. Defibrination and ether extraction of both normal and hemophilic dog plasma "generated" clotting activity which shortened the clotting time of hemophilic plasma and was active in the thromboplastin generation test. The activity "generated" by defibrination and ether extraction of dog plasma was adsorbed by a BaSO(4) suspension and shown, therefore, not to be the anti-hemophilic factor (AHF). Transfusion of ether-extracted normal or hemophilic dog plasma into hemophilic dogs had no effect on the prothrombin utilization rate, unlike untreated normal plasma which had a marked effect. Thus, four of the main lines of evidence supporting the "anticephalin" hypothesis were duplicated in the dog. However, by extending the experiments it was found that all were explainable on bases other than the presence of "anticephalin." Such an hypothesis is not necessary, therefore, to explain the pathogenesis of canine hemophilia. The apparent identity of hemophilia in the two species suggests that the hypothesis is also not applicable to humans.

Entities:  

Keywords:  HEMOPHILIA/etiology and pathogenesis

Mesh:

Year:  1957        PMID: 13449237      PMCID: PMC2136750          DOI: 10.1084/jem.106.2.273

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  22 in total

1.  Physiologic basis of transfusion therapy in hemophilia.

Authors:  K M BRINKHOUS; G D PENICK; R D LANGDELL; R H WAGNER; J B GRAHAM
Journal:  AMA Arch Pathol       Date:  1956-01

2.  Ultracentrifugal separation of coagulation factors: platelet cofactors and inhibitors.

Authors:  S A JOHNSON; E DEUTSCH; W H SEEGERS
Journal:  Am J Physiol       Date:  1954-10

3.  Activation of purified prothrombin with platelets combined with various crude biochemical preparations.

Authors:  W H SEEGERS; S A JOHNSON; C FELL; N ALKJAERSIG
Journal:  Am J Physiol       Date:  1954-07

4.  Serum accelerator factors and antihemophilic factor (AHF) in early phases of clotting.

Authors:  J B GRAHAM; R D LANGDELL; F C MORRISON; K M BRINKHOUS
Journal:  Proc Soc Exp Biol Med       Date:  1954-10

5.  Use of purified prothrombin in the study of hemophilia and plasma thromboplastin component (PTC) deficiency.

Authors:  S A JOHNSON; W H SEEGERS
Journal:  J Appl Physiol       Date:  1954-01       Impact factor: 3.531

6.  Activation of purified prothrombin with hemophilic plasma.

Authors:  S A JOHNSON
Journal:  Am J Clin Pathol       Date:  1953-09       Impact factor: 2.493

7.  The thromboplastin generation test.

Authors:  R BIGGS; A S DOUGLAS
Journal:  J Clin Pathol       Date:  1953-02       Impact factor: 3.411

8.  Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure.

Authors:  R D LANGDELL; R H WAGNER; K M BRINKHOUS
Journal:  J Lab Clin Med       Date:  1953-04

9.  Hemophilia and the hemophilioid states.

Authors:  K M BRINKHOUS; J B GRAHAM
Journal:  Blood       Date:  1954-03       Impact factor: 22.113

10.  Hemophilic syndromes and hemophilia.

Authors:  L M TOCANTINS
Journal:  Blood       Date:  1954-03       Impact factor: 22.113

View more
  3 in total

1.  The value of animal models.

Authors:  T C Jones
Journal:  Am J Pathol       Date:  1980-12       Impact factor: 4.307

2.  [Hemophilia, deficiency condition or excess of antibodies?].

Authors:  E Hecht
Journal:  Klin Wochenschr       Date:  1966-07-15

3.  The defect in hemophilic and von Willebrand's disease plasmas studied by a recombination technique.

Authors:  H A Cooper; R H Wagner
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.